Amarin Corp Plc\uk last reported quarterly results on Oct 28, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $39.5 million (-20.4% year over year) and diluted EPS of $0.00. It usually reports 8–29 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–29 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
40
-20.4%
|
0
+103.2%
|
0.00
+100.0%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
42
-42.0%
|
-8
+45.9%
|
-0.02
+33.3%
|
|
Apr 29, 2026
29 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
45
+7.4%
|
-11
+33.0%
|
-0.03
+25.0%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
49
-21.0%
|
-1
+97.5%
|
-0.00
+97.5%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
50
+17.4%
|
-8
+69.2%
|
-0.02
+66.7%
|
|
Jul 30, 2025
30 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
73
+7.8%
|
-14
-1029.0%
|
-0.03
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
42
-25.7%
|
-16
-57.7%
|
-0.04
-100.0%
|
|
Mar 12, 2025
71 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
62
-16.6%
|
-49
-741.0%
|
-0.12
-734.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Dublin 2
- SEC filer status
- Accelerated filer
- SEC CIK
- 897448
- Former names
- AMARIN CORP PLC\UK (until Oct 28, 2026); AMARIN PHARMACEUTICALS PLC (until Jul 13, 2000); ETHICAL HOLDINGS PLC (until Jan 28, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.